JP2023517312A5 - - Google Patents

Info

Publication number
JP2023517312A5
JP2023517312A5 JP2022553214A JP2022553214A JP2023517312A5 JP 2023517312 A5 JP2023517312 A5 JP 2023517312A5 JP 2022553214 A JP2022553214 A JP 2022553214A JP 2022553214 A JP2022553214 A JP 2022553214A JP 2023517312 A5 JP2023517312 A5 JP 2023517312A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
composition according
humans
hiv infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022553214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517312A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/051765 external-priority patent/WO2021176367A1/en
Publication of JP2023517312A publication Critical patent/JP2023517312A/ja
Publication of JP2023517312A5 publication Critical patent/JP2023517312A5/ja
Pending legal-status Critical Current

Links

JP2022553214A 2020-03-06 2021-03-03 ヒト免疫不全ウイルスの複製阻害剤 Pending JP2023517312A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062985946P 2020-03-06 2020-03-06
US62/985,946 2020-03-06
PCT/IB2021/051765 WO2021176367A1 (en) 2020-03-06 2021-03-03 Inhibitors of human immunodeficiency virus replication

Publications (2)

Publication Number Publication Date
JP2023517312A JP2023517312A (ja) 2023-04-25
JP2023517312A5 true JP2023517312A5 (cg-RX-API-DMAC7.html) 2024-03-13

Family

ID=74870854

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022553214A Pending JP2023517312A (ja) 2020-03-06 2021-03-03 ヒト免疫不全ウイルスの複製阻害剤

Country Status (4)

Country Link
US (1) US12703699B2 (cg-RX-API-DMAC7.html)
EP (1) EP4114527A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023517312A (cg-RX-API-DMAC7.html)
WO (1) WO2021176367A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53973A (fr) 2018-10-24 2022-02-09 Viiv Healthcare Uk No 5 Ltd Inhibiteurs de la réplication du virus de l'immunodéficience humaine
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於hiv之治療性化合物
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
WO2025169059A1 (en) 2024-02-05 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
CA2840095A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
EP2943493B1 (en) 2013-01-09 2017-08-02 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
TWI694071B (zh) * 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
US10035760B2 (en) 2013-10-24 2018-07-31 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
US9873680B2 (en) 2014-08-29 2018-01-23 Gilead Sciences, Inc. Therapeutic compounds
US9855230B2 (en) 2014-09-09 2018-01-02 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
TWI695003B (zh) * 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
PT3286166T (pt) 2015-04-23 2020-08-18 Viiv Healthcare Uk No 5 Ltd Inibidores de replicação do vírus da imunodeficiência humana
AU2016250662A1 (en) 2015-04-23 2017-11-16 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
LT3347352T (lt) 2016-08-19 2019-08-12 Gilead Sciences, Inc. Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui
TW201906834A (zh) 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
TW202024061A (zh) 2017-08-17 2020-07-01 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
KR102847339B1 (ko) 2018-02-16 2025-08-19 길리애드 사이언시즈, 인코포레이티드 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
WO2019198024A1 (en) 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
CA3108633A1 (en) 2018-08-09 2020-02-13 Viiv Healthcare Uk (No 5) Limited Inhibitors of human immunodeficiency virus replication
WO2020058844A1 (en) 2018-09-20 2020-03-26 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
ES2969030T3 (es) 2018-10-29 2024-05-16 Viiv Healthcare Uk No 5 Ltd Derivados de quinazolinil-indazol y su uso como inhibidores de replicación de virus de inmunodeficiencia humana
JP2022506399A (ja) 2018-11-05 2022-01-17 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
US20210395248A1 (en) 2018-11-05 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
UY38559A (es) 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
EP3986561B1 (en) 2019-06-19 2024-02-14 VIIV Healthcare UK (No.5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
IL293566A (en) 2019-12-09 2022-08-01 Viiv Healthcare Co Pharmaceutical preparations containing Cabotgravir
WO2021176366A1 (en) 2020-03-06 2021-09-10 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP4135702B1 (en) 2020-04-15 2026-06-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Similar Documents

Publication Publication Date Title
KR102828456B1 (ko) 벤조피라졸 화합물 및 이의 유사체
FI83312C (fi) Foerfarande foer framstaellning av terapeutiskt aktiva 7-(1-pyrrolidinyl)-1-cyklopropyl-6,8-difluor-1,4 -dihydro-4-oxo-3-kinolinkarboxylsyror och deras salter.
JP4523281B2 (ja) Hivインテグラーゼ阻害薬として有用なヒドロキシナフチリジノンカルボキサミド類
CN108727378A (zh) 新型异喹啉类化合物及其医药用途
CN117715906A (zh) 胰高血糖素样肽-1受体调节剂及其用途
JP2023517043A5 (cg-RX-API-DMAC7.html)
CN110461858A (zh) 酰基核苷膦酸酯、其前药及其作为药物的用途
JP2022552156A5 (cg-RX-API-DMAC7.html)
EP3962603A1 (en) Inhibitors of human immunodeficiency virus replication
JP2022551256A5 (cg-RX-API-DMAC7.html)
JP2024528962A (ja) シアノピリジンおよびシアノピリミジンbcl6分解剤
JP2025515833A5 (cg-RX-API-DMAC7.html)
US20030119848A1 (en) Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient
JP7618642B2 (ja) インターロイキンの調節におけるプロドラッグ
IL296902A (en) n-Heteroarylalkyl-2-(heterocyclyl and heterocyclylmethyl)acetamide derivatives as sstr4 agonists
JP2025538197A (ja) Aak1阻害剤を含有する医薬組成物
JP2025518533A (ja) インテグリン阻害剤の安定化
CN1183778A (zh) 喹啉羧酸衍生物
JP7836529B2 (ja) 腸内分解性共薬、その調製及び使用
JP2006512364A5 (cg-RX-API-DMAC7.html)
CN111936488B (zh) 用于治疗寄生虫感染的新颖化合物
CN111087409B (zh) 一种喹诺酮类化合物及其制备方法和应用
JP7446424B2 (ja) スルホニル尿素環置換単環式β-ラクタム系抗生物質
JP3718262B2 (ja) ホスフィン酸誘導体、その調製方法およびその使用
CN113082023B (zh) P2x3抑制剂和p2x4抑制剂的药物组合及其应用